Boehringer Ingelheim has established a new EUR 50-million+ ($62.2 million+) pilot-plant facility for the production of newly developed APIs in Biberach, Germany. The new technical center will have a useable area of approximately 2700-m² (29062.56 ft²) and will host four manufacturing bays including four synthesis laboratories, which will handle the transfer of processes from laboratory to technical scale. The facility will have 15 chemical reactors with volumes of 100 to 300 liters, and is scheduled for completion in early 2014. Read More

Catalent Pharma Solutions has completed construction of its newly renovated 3300-ft² aseptic fill–finish manufacturing facility at Research Triangle Park, North Carolina. The product-development group conducts preformulation, formulation development, process development, and manufacturing support in addition to offering analytical development and stability capabilities. The sterile clinical manufacturing suite will provide Class A manufacturing space containing a flexible aseptic vial-filling line capable of producing Phase I and Phase II clinical-trial materials. These fill–finish facilities are designed to comply with global GMP requirements. Read More

Eli Lilly has officially opened the Lilly China Research and Development Center (LCRDC) in Shanghai. The goal of the LCRDC is to discover diabetes medicines with mechanisms of action that can be tailored specifically for the Chinese population to delay the progression of the disease. Read More

Siegfried has acquired Alliance Medical Products (AMP), a sterile manufacturer, for $58 million. The purchase price specifies a contingent earn-out consideration subject to AMP meeting defined profitability goals for the fiscal year ended Dec. 31, 2013. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More